Wilding 2021 — STEP 1 Semaglutide Pivotal

New England Journal of Medicine

Wilding JPH, et al.

Summary

-14.9% vs -2.4% weight; basis for Wegovy approval

Study Details

Study Design

Phase 3 double-blind RCT

Indication

Obesity without diabetes

Intervention

Semaglutide 2.4 mg weekly

Species

Human

Sample Size

1,961 subjects

Risk of Bias Assessment

Industry-sponsored